NCT04308395

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Sol-Gel Technologies, Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.

Conditions

• Basal Cell Nevus Syndrome

Interventions

Type	Name	Description
DRUG	Patidegib Topical Gel, 2%	Patidegib Topical Gel, 2%

Timeline

• Start date: 2020-06-03
• Primary completion: 2021-07-14
• Completion: 2021-07-14
• First posted: 2020-03-16
• Last updated: 2024-09-24
• Results posted: 2024-09-24

Locations

37 sites across 9 countries: United States, Belgium, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study